Lea Clayton, MD
Family Medicine · Moody, ALNPI 1376651992
Payments from drug & device makers
Across 400 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Novo Nordisk$630
- Lilly USA, LLC$495
- AbbVie$429
- Amgen$402
- Amarin Pharma, Inc.$350
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,466100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 85 | $1,560 |
| Novo Nordisk | 45 | $630 |
| Lilly USA, LLC | 33 | $495 |
| AbbVie(2 entities) | 27 | $429 |
| Amgen | 26 | $402 |
| Amarin Pharma, Inc. | 23 | $350 |
| Pfizer | 29 | $335 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $314 |
| Esperion Therapeutics, Inc. | 9 | $271 |
| Merck | 12 | $190 |
| Abbott | 7 | $137 |
| Boehringer Ingelheim | 10 | $134 |
| Sanofi-aventis U.S. LLC | 8 | $132 |
| Kowa Pharmaceuticals America, Inc. | 10 | $128 |
| Teva Pharmaceuticals USA, Inc. | 9 | $114 |
| Genentech USA, Inc. | 6 | $114 |
| Jazz Pharmaceuticals Inc. | 6 | $89 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $67 |
| Corium, LLC | 3 | $65 |
| Dexcom, Inc. | 3 | $56 |
| Aytu Biopharma, Inc. | 3 | $49 |
| AstraZeneca | 3 | $44 |
| Eisai Inc. | 3 | $42 |
| Adlon Therapeutics L.p. | 2 | $36 |
| Shire North American Group Inc | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Paratek Pharmaceuticals, Inc. | 2 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Neos Therapeutics, LP | 1 | $19 |
| Novartis | 1 | $18 |
| Medtronic | 1 | $17 |
| Bayer | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Global Blood Therapeutics, Inc. | 1 | $14 |
| Strongbridge US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,466 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $90,911 |
| MounjaroTirzepatide | 53 | $61,606 |
| JanuviaSitagliptin Phosphate | 68 | $52,261 |
| TrulicityDulaglutide | 38 | $44,194 |
| JardianceEmpagliflozin | 36 | $40,124 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $35,259 |
| EliquisApixaban | 34 | $27,441 |
| XareltoRivaroxaban | 30 | $19,748 |
| FarxigaDapagliflozin Propanediol | 21 | $14,609 |
| LinzessLinaclotide | 16 | $13,371 |
| Repatha SureclickEvolocumab | 13 | $8,897 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $8,608 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $7,734 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,657 |
| Rosuvastatin Calcium | 216 | $5,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $495 | $105,80091 claims |
| Novo NordiskOzempic | $630 | $90,91159 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,560 | $54,28683 claims |
| MerckJanuvia | $190 | $52,26168 claims |
| Boehringer IngelheimJardiance | $134 | $40,12436 claims |
| PfizerEliquis | $335 | $27,44134 claims |
| Johnson & JohnsonXarelto | $16 | $19,74830 claims |
| AbbVieLinzess, Synthroid | $429 | $14,72333 claims |
| AstraZenecaFarxiga | $44 | $14,60921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Moody
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.